The NCPE recommends reimbursement of Sovaldi® for certain subgroups.
The NCPE do not recommend reimbursement of nab-paclitaxel (Abraxane®).
The NCPE does not recommend reimbursement under the submitted pricing structure.
The NCPE does not recommend reimbursement of lixisenatide for patients with type 2 diabetes mellitus at the submitted price.
The NCPE recommends reimbursement of alemtuzumab (Lemtrada®).
The NCPE do not recommend reimbursement of trastuzumab emtansine (Kadcyla®) at the submitted price.
The NCPE considers dabrafenib (Tafinlar®) to be cost effective compared to vemurafenib.
The NCPE does not recommend regorafenib (Stivarga®) as a cost-effective treatment option.
The NCPE does not consider Suboxone® to be cost-effective compared to methadone for the treatment of opioid dependence.
The NCPE does not recommend reimbursement of teriflunomide
(Aubagio®) at the current price.